Stoke Therapeutics (STOK) News Today $9.36 -0.10 (-1.06%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Assenagon Asset Management S.A. Raises Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)Assenagon Asset Management S.A. grew its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,350,925 shares of the compJanuary 18 at 3:40 AM | marketbeat.comReusable rocket startup Stoke raised another massive round: $260MJanuary 16, 2025 | msn.comStoke Therapeutics (NASDAQ:STOK) Stock Price Up 9.7% - Time to Buy?Stoke Therapeutics (NASDAQ:STOK) Trading Up 9.7% - What's Next?January 15, 2025 | marketbeat.comQ1 EPS Estimates for Stoke Therapeutics Raised by WedbushJanuary 12, 2025 | americanbankingnews.comStoke Therapeutics' (STOK) "Buy" Rating Reiterated at HC WainwrightJanuary 11, 2025 | americanbankingnews.comWedbush Research Analysts Raise Earnings Estimates for STOKStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Research analysts at Wedbush lifted their Q1 2025 earnings per share estimates for Stoke Therapeutics in a research note issued on Tuesday, January 7th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share ofJanuary 10, 2025 | marketbeat.comWhat is Wedbush's Forecast for STOK FY2029 Earnings?Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at Wedbush issued their FY2029 earnings estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Tuesday, January 7th. Wedbush analyst L. Chico forecasts that the company will post earnings oJanuary 9, 2025 | marketbeat.comPositive Outlook on Stoke Therapeutics: Strategic Alignment and Promising Data Reinforce Long-Term Growth PotentialJanuary 9, 2025 | markets.businessinsider.comThe Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 ExpertsJanuary 8, 2025 | benzinga.comStoke Therapeutics’ Promising Potential: Buy Rating Backed by Strong Phase 3 Trial Design and Positive Early ResultsJanuary 8, 2025 | markets.businessinsider.comStoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | businesswire.comStoke Therapeutics (NASDAQ:STOK) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday.January 8, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Stoke Therapeutics (NASDAQ:STOK)Needham & Company LLC reissued a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday.January 8, 2025 | marketbeat.comStoke Therapeutics finalizes EMPEROR study program with regulatory agenciesJanuary 7, 2025 | markets.businessinsider.comStoke Therapeutics negative reaction after STK-001 update overdone, says ChardanJanuary 7, 2025 | msn.comBuy Rating on Stoke Therapeutics Driven by Promising Phase 3 Trial and Financial StabilityJanuary 7, 2025 | markets.businessinsider.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Time to Sell?Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Here's WhyJanuary 7, 2025 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by AnalystsShares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have received a consensus rating of "Buy" from the ten analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and oneJanuary 6, 2025 | marketbeat.comFranklin Resources Inc. Cuts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)Franklin Resources Inc. lowered its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 98.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,314 shares of the company's stoJanuary 2, 2025 | marketbeat.comGeode Capital Management LLC Buys 76,661 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)Geode Capital Management LLC increased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 9.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 870,831 shares of the company's stock after purchasingJanuary 1, 2025 | marketbeat.comBarclays PLC Purchases 47,239 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)Barclays PLC increased its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 145.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 79,740 shares of the company's stock after buying an addDecember 31, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Down 2.9% - Here's WhyStoke Therapeutics (NASDAQ:STOK) Stock Price Down 2.9% - Here's WhyDecember 24, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by State Street CorpState Street Corp raised its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 8.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,728,888 shares of the company's stock after acquiring an additional 137,1December 24, 2024 | marketbeat.comChardan Capital Initiates Coverage of Stoke Therapeutics (STOK) with Buy RecommendationDecember 20, 2024 | msn.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Here's What HappenedStoke Therapeutics (NASDAQ:STOK) Shares Gap Down - Time to Sell?December 20, 2024 | marketbeat.comChardan Capital Initiates Coverage on Stoke Therapeutics (NASDAQ:STOK)Chardan Capital began coverage on shares of Stoke Therapeutics in a report on Friday. They set a "buy" rating and a $24.00 price objective for the company.December 20, 2024 | marketbeat.comJane Street Group LLC Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)Jane Street Group LLC boosted its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 338.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 330,442 shares of the company's stock after buying an additionDecember 19, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Stock Price Down 5% - Here's WhyStoke Therapeutics (NASDAQ:STOK) Shares Down 5% - Here's WhyDecember 18, 2024 | marketbeat.comCompanies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In GrowthDecember 17, 2024 | uk.finance.yahoo.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Fmr LLCFmr LLC trimmed its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 18.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 322,949 shares of the company's stock after selling 75,070 shares durinDecember 14, 2024 | marketbeat.comStoke Space hotfires rocket engine on new vertical test stand — a ‘very big deal’ for Washington startupDecember 13, 2024 | msn.comStoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 2,586 SharesDecember 12, 2024 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Buy" from AnalystsShares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have been assigned a consensus rating of "Buy" from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have given a buyDecember 12, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) CEO Sells $78,852.60 in StockDecember 11, 2024 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Shares Bought by BNP Paribas Financial MarketsBNP Paribas Financial Markets boosted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 1,589.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 76,154 shares of the company'December 11, 2024 | marketbeat.comStoke Therapeutics: Promising Developments in Seizure Treatment Bolster Buy RatingDecember 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Silence Therapeutics (SLN)December 10, 2024 | markets.businessinsider.comStoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet SyndromeDecember 6, 2024 | businesswire.comPreveCeutical Medical Inc.: BioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry TichoDecember 5, 2024 | finanznachrichten.deStoke Therapeutics (NASDAQ:STOK) Stock Quotes, Forecast and News SummaryDecember 5, 2024 | benzinga.comBioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry TichoDecember 5, 2024 | finance.yahoo.comRTW Investments LP Buys 427,447 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)RTW Investments LP raised its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 10.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,652,285 shares of the company's stock after acquiring an additional 427,447 sharDecember 5, 2024 | marketbeat.comStoke Therapeutics Shares Rise Premarket on Key FDA DesignationDecember 5, 2024 | marketwatch.comStoke Therapeutics Receives Breakthrough Therapy Designation For ZorevunersenDecember 5, 2024 | markets.businessinsider.comStoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet SyndromeDecember 5, 2024 | finance.yahoo.comBarry Ticho Sells 10,000 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) StockDecember 4, 2024 | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Buy" by BrokeragesStoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been given an average rating of "Buy" by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and oNovember 17, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Down 8.3% - Here's WhyStoke Therapeutics (NASDAQ:STOK) Trading Down 8.3% - What's Next?November 15, 2024 | marketbeat.comLos Angeles Capital Management LLC Purchases 36,240 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)Los Angeles Capital Management LLC boosted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 54.3% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 103,005 shares of the company's stock afteNovember 15, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for STOK FY2024 Earnings?Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at HC Wainwright boosted their FY2024 earnings per share estimates for Stoke Therapeutics in a research report issued on Wednesday, November 6th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($2.00November 8, 2024 | marketbeat.com Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Media Mentions By Week STOK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STOK News Sentiment▼0.450.46▲Average Medical News Sentiment STOK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STOK Articles This Week▼36▲STOK Articles Average Week Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BEAM News IDYA News AGIO News IOVA News TARS News AKRO News BLTE News IRON News AMPH News WVE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STOK) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STOK Stock Alerts